TAK1 regulates endothelial cell necroptosis and tumor metastasis.


Journal

Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 13 09 2018
accepted: 21 12 2018
revised: 18 12 2018
pubmed: 27 1 2019
medline: 29 9 2020
entrez: 27 1 2019
Statut: ppublish

Résumé

Formation of metastases is the major cause of death in patients diagnosed with cancer. It is a complex multistep process, including tumor cell migration, intravasation, survival in the circulation, and extravasation. Previously it was shown that tumor cell-induced endothelial necroptosis promotes tumor cell extravasation and metastasis. Here, we identified endothelial TGF-β-activated kinase 1 (TAK1) as a critical regulator of endothelial necroptosis and metastasis. Human and murine endothelial cells lacking TAK1 exhibit higher levels of necroptosis both in vitro and in vivo, and mice with endothelial cell-specific loss of TAK1 are more prone to form metastases. Endothelial RIPK3, a key component of the necroptotic machinery, was upregulated in mice with endothelial TAK1-deficiency, and endothelial knockout of RIPK3 reverted the effects of TAK1-deficiency. Moreover, altered expression levels of TAK1 and RIPK3 in pulmonary endothelial cells of mice bearing primary tumors correlated with increased endothelial necroptosis and metastasis. Together, our data suggest an important protective role for endothelial TAK1 in tumor progression by keeping endothelial necroptosis in check.

Identifiants

pubmed: 30683914
doi: 10.1038/s41418-018-0271-8
pii: 10.1038/s41418-018-0271-8
pmc: PMC6748133
doi:

Substances chimiques

RIPK3 protein, human EC 2.7.11.1
Receptor-Interacting Protein Serine-Threonine Kinases EC 2.7.11.1
Ripk3 protein, mouse EC 2.7.11.1
MAP Kinase Kinase Kinases EC 2.7.11.25
MAP kinase kinase kinase 7 EC 2.7.11.25

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1987-1997

Subventions

Organisme : Deutsche Krebshilfe (German Cancer Aid)
ID : 111230
Organisme : Deutsche Krebshilfe (German Cancer Aid)
ID : 111230

Références

Cancer Cell. 2002 Oct;2(4):289-300
pubmed: 12398893
J Exp Med. 2004 Sep 20;200(6):771-82
pubmed: 15381730
Clin Exp Metastasis. 2004;21(3):265-73
pubmed: 15387377
Nat Immunol. 2005 Nov;6(11):1087-95
pubmed: 16186825
Nat Cell Biol. 2006 Dec;8(12):1369-75
pubmed: 17128264
Clin Exp Metastasis. 2008;25(4):305-24
pubmed: 17906932
Cell. 2008 Feb 8;132(3):344-62
pubmed: 18267068
Mol Cell. 2008 Jun 20;30(6):689-700
pubmed: 18570872
J Biol Chem. 2008 Sep 19;283(38):26161-8
pubmed: 18606807
J Exp Med. 2009 Feb 16;206(2):411-20
pubmed: 19171764
J Immunol. 2009 May 15;182(10):6095-104
pubmed: 19414761
Science. 2009 Jul 17;325(5938):332-6
pubmed: 19498109
Cancer Res. 2009 Oct 1;69(19):7529-37
pubmed: 19773447
Cell Death Differ. 2011 Apr;18(4):656-65
pubmed: 21052097
Mol Cell. 2011 Aug 5;43(3):449-63
pubmed: 21737330
Blood. 2011 Oct 6;118(14):3990-4002
pubmed: 21841165
Cancer Cell. 2012 Jul 10;22(1):91-105
pubmed: 22789541
Trends Pharmacol Sci. 2012 Oct;33(10):522-30
pubmed: 22795313
Blood. 2012 Nov 1;120(18):3846-57
pubmed: 22972987
Mol Cell Biol. 2013 Feb;33(3):582-95
pubmed: 23166301
Dev Cell. 2013 May 28;25(4):427-34
pubmed: 23664862
Cancer Cell. 2013 Jul 8;24(1):130-7
pubmed: 23810565
Cell Death Differ. 2013 Oct;20(10):1381-92
pubmed: 23892367
Nat Rev Cancer. 2013 Dec;13(12):858-70
pubmed: 24263189
J Cell Biol. 2014 Feb 17;204(4):607-23
pubmed: 24535827
Mol Cancer. 2014 Feb 24;13:35
pubmed: 24565101
Cancer Cell. 2014 Apr 14;25(4):501-15
pubmed: 24735924
Cell Death Differ. 2014 Nov;21(11):1667-76
pubmed: 25146924
Nature. 2015 Jan 15;517(7534):311-20
pubmed: 25592536
Oncotarget. 2015 Apr 20;6(11):8474-90
pubmed: 25893379
Nat Commun. 2015 Apr 30;6:6993
pubmed: 25925867
Nat Med. 2016 Feb;22(2):175-82
pubmed: 26726877
Cell Death Dis. 2016 Apr 14;7:e2196
pubmed: 27077812
Nat Commun. 2016 Jun 21;7:11869
pubmed: 27323669
Nature. 2016 Aug 11;536(7615):215-8
pubmed: 27487218
Cell Death Dis. 2016 Sep 29;7(9):e2381
pubmed: 27685625
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
Dig Dis Sci. 2017 Apr;62(4):944-957
pubmed: 28194669
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Biomed Rep. 2017 Apr;6(4):429-434
pubmed: 28413641
Mol Med Rep. 2017 Jul;16(1):755-763
pubmed: 28560435
Nat Commun. 2017 Aug 25;8(1):359
pubmed: 28842570
Cancer Cell. 2017 Sep 11;32(3):282-293
pubmed: 28898694
Oncol Rep. 2017 Nov;38(5):2735-2740
pubmed: 29048684
Future Oncol. 2018 Feb;14(5):461-469
pubmed: 29327611
J Exp Med. 2018 Apr 2;215(4):1023-1034
pubmed: 29500178
Genes Dev. 2018 Mar 1;32(5-6):327-340
pubmed: 29593066

Auteurs

Lida Yang (L)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany.

Sayali Joseph (S)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany.

Tianliang Sun (T)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany.
Novartis Institutes for Biomedical Research, Novartis Pharma AG, WSJ360.4.20 Novartis Campus, 4056, Basel, Switzerland.

Julia Hoffmann (J)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany.
Charité Universitätsmedizin Berlin, Institute of Pathology, Charitéplatz 1, 10177, Berlin, Germany.

Sophia Thevissen (S)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany.

Stefan Offermanns (S)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany. Stefan.Offermanns@mpi-bn.mpg.de.
J.W. Goethe University Frankfurt, Center for Molecular Medicine, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany. Stefan.Offermanns@mpi-bn.mpg.de.

Boris Strilic (B)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany. Boris.Strilic@mpi-bn.mpg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH